Royalty Pharma (RPRX) Divestments (2020 - 2026)

Royalty Pharma has disclosed Divestments across 7 years of filings, most recently posting $42.3 million for Q1 2026.

• Divestments for Q1 2026 came in at $42.3 million, up 16.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.6 million (up 103.3% YoY), and the FY2025 annual result was $105.1 million, up 344.77% from the prior year.
• Divestments came in at $42.3 million for Q1 2026 at Royalty Pharma, up from $5.0 million in the prior quarter.
• In the past five years, Divestments ranged from a high of $62.4 million in Q2 2025 to a low of $905000.0 in Q3 2025.
• The 5-year median for Divestments is $5.0 million (2025), against an average of $15.3 million.
• Peak annual rise in Divestments reached 1500.0% in 2025, while the deepest fall reached 91.77% in 2025.
• Royalty Pharma's Divestments stood at $5.8 million in 2022, then fell by 19.71% to $4.7 million in 2023, then plunged by 30.34% to $3.2 million in 2024, then surged by 53.95% to $5.0 million in 2025, then jumped by 747.14% to $42.3 million in 2026.
• The last three Divestments figures came in at $42.3 million (Q1 2026), $5.0 million (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.